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Abstract
Cigarette smoking causes cardiovascular disease and is associated with poor kidney function in individuals with diabetes mellitus and primary kidney diseases. However, the association of smoking on patients with atherosclerotic renal artery stenosis has not been studied.
The current study utilized data from the Cardiovascular Outcomes in Renal Atherosclerotic
Lesions (CORAL, NCT00081731) clinical trial to evaluate the effects of smoking on the risk
of cardio-renal events and kidney function in this population. Baseline data showed that
smokers (n = 277 out of 931) were significantly younger at enrollment than non-smokers
(63.3±9.1 years vs 72.4±7.8 years; p<0.001). In addition, patients who smoke were also
more likely to have bilateral renal artery stenoses and peripheral vascular disease (PVD).
Longitudinal analysis showed that smokers experienced composite endpoint events
(defined as first occurrence of: stroke; cardiovascular or renal death; myocardial infarction;
hospitalization for congestive heart failure; permanent renal replacement; and progressive
renal insufficiency defined as 30% reduction of GFR from baseline sustained for  60 days) at
a substantially younger age compared to non-smokers (67.1±9.0 versus 76.1±7.9, p<0.001).
Using linear regression and generalized linear modeling analysis controlled by age, sex, and
ethnicity, smokers had significantly higher cystatin C levels (1.3±0.7 vs 1.2±0.9, p<0.01)
whereas creatinine and estimated glomerular filtration rate (eGFR) were not different from
non-smokers. From these data we conclude that smoking has a significant association with
deleterious cardio-renal outcomes in patients with renovascular hypertension.
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Introduction
Despite tobacco control programs aimed at reducing consumption, cigarette smoking still
causes 443,000 deaths each year in the United States according to the Centers for Disease Control and Prevention [1, 2]. Cigarette smoking is widely known to have adverse health effects on
cardiovascular disease, chronic obstructive lung disease, liver disease and cancer [3–5], and
may have adverse effects on kidney function [6]. The deleterious effects of smoking on kidney
function have been reported in patients with diabetes mellitus and primary kidney diseases
including polycystic kidney disease, glomerulonephritis and lupus nephritis[3–9]. Recently,
epidemiologic studies demonstrated that smoking increases the risk of chronic kidney disease
progression and kidney failure in patients with diabetes and hypertension [10, 11]. However,
the importance of active smoking in patients with renal artery stenosis has not been described.
Renal artery stenosis (RAS) is a common problem and is present in roughly 1–5% of the 60
million Americans with hypertension [12–14]. This is considered a disease of older persons
with most studies having a mean age for RAS greater than 70 years [15]. Low kidney function
is common and there is a strikingly high rate of adverse cardiovascular events and mortality
[16]. Smoking is a known risk factor for atherosclerosis, and a smoking history is typical in
patients with renal artery stenosis [17]. However, the association between smoking and cardio-renal outcomes has not been studied in patients with atherosclerotic renal disease. This
study used data from the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL,
NCT00081731) [18] clinical trial to evaluate changes in cardio-renal outcomes and secondary
parameters in RAS patients who are active smokers.

Materials and methods
Study population
CORAL is a prospective, international, multicenter clinical trial that randomly assigned 931
participants with atherosclerotic renal artery stenosis who received optimal medical therapy
to stenting versus no stenting from May 2005 through January 2010. The detailed description and analysis of the endpoints have previously been described [18]. For the current
study the primary outcome was the composite endpoint defined as the first occurrence of
any secondary endpoints (cardiovascular or renal death; myocardial infarction (ST segment
elevation or silent MI); stroke; congestive heart failure (CHF); progressive renal insufficiency (30% decline in GFR over the period of 6 months [19]); and permanent renal
replacement. Active cigarette smoking was defined as tobacco use within the year prior to
enrollment in the study. The study was approved by the Institutional Review Board at the
University of Toledo (IRB104827). All of the centers followed the institutional and study
guidelines. All participating patients have provided written informed consent. Detailed
study entry criteria have been published [18]. Patients with renal artery stenosis of at least
60% were eligible if they had hypertension while receiving two or more antihypertensive
agents or had an estimated glomerular filtration rate (eGFR) less than 60 ml/minute/1.73m2
[18]. Angiograms were analyzed for verification of stenosis by the Angiography Core Lab
for the study at the University of Virginia [18].

Statistical analysis
Study data are presented as continuous (mean ± Standard Deviation [SD]), categorical (number and percentage), and medians (with interquartile range [IQR]). Comparisons of continuous data were evaluated with ANOVA and two-sample t tests, while for categorical variables,
the Fisher exact test was used and odds ratios (OR) were calculated. Statistical significance was
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defined as a p-value <0.05. Data was tested for normal distribution using the Shapiro-Wilk
test and nonparametric Mann-Whitney U rank test was used if the assumption of normality
was violated. Where possible, the data was log-transformed to approximate a normal distribution and parametric analysis was undertaken. All analyses were performed using R software
(version 3.0.0) and SAS (version 9.3).

Multiple variable models and longitudinal analyses
Univariate analysis was performed comparing smokers to non-smokers on baseline characteristics, and variables with p<0.05 were included in multiple variable analyses using multiple linear regression model and generalized linear model (GLM) with application of
stepwise model selection. Each of the baseline factors were analyzed as response variables
adjusted for age and smoking status to correct for potential age bias and to guide in the
selection of factors for the multivariable models. All multiple variable analyses were controlled for age, sex, ethnicity (Hispanic/Latino) and body mass index (BMI, weight in kilograms divided by the square of the height in meters). Longitudinal analyses using linear
mixed effect model were performed using time (continuous) as the random coefficient to
assess the effects of smoking on measures of kidney function (eGFR, cystatin C, serum creatinine concentrations) and damage (urine albumin-to-creatinine ratio [UACR]) up to 5
years. The models were checked using two versions of the mixed effect model: one version
contained both time as a random coefficient effect and fixed effects, while the other version
considered time as a fixed event. ANOVA was used to compare the residual sums of squares
for the 2 models. The random effect model was selected as it yielded lower AIC and BIC
measures.

Event analysis
Due to the age discrepancy between smokers and non-smokers, we selected age-at-event as
the time-scale for hazard risk since the covariate of interest (smoking) is not independent of
age and the Cox model using time-to-event may incur bias even when adjusting for age
[20–23]. Moreover, smokers accrue risk over their lifetime that would not be reflected if
time-to-events were used as the response. Age-at-event outcomes were expressed using
Kaplan-Meier estimates with comparisons between smoking status groups using the logrank statistic. Hazard risk ratios were calculated using the Cox proportional-hazards model,
and the comparison between smoking groups was evaluated using both survival time and
age-at-event as the response variables. Model diagnostics were performed using the CoxSnell residual plot test to check for goodness of fit. The proportional hazards assumption
tests from the R function cox.zph in the survival package for all the survival models had pvalues >0.05 indicating that the null hypothesis of proportional hazards was not rejected.
The extended Cox model was used to test for interaction among model predictors and time.
The time-dependent covariates were generated by building interactions of the predictors
and a function of survival age (age-to-event), and were included in the models. The p-values
for all time-covariate interactions in all of the survival models were greater than 0.05, confirming the null hypothesis assumption of proportional hazards, and indicating that the fitted Cox regression hazard models are adequate. The predicted probability of the binary
occurrence of the composite endpoint or any of the secondary endpoint events was calculated using receiver operating characteristic (ROC) for logistic regression with adjustment
for age, sex, ethnicity and BMI.
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Results
Baseline characteristics comparison of smokers and non-smokers
The CONSORT flow diagram of CORAL study is shown in Fig 1. There were 277 (30%) smokers among the 931 participants in the CORAL trial. The median follow-up period was 43
months (interquartile range of 31 to 55). Smokers were younger than non-smoking participants at enrollment (63.3 ± 9.1 years old versus 72.4 ± 7.8 years old, p<0.001; Fig 2). Other
baseline characteristics shown in Table 1 demonstrate no difference in renal artery stenosis
severity between groups based on degree of stenosis (68.8±11.3% versus 68.5±11.7%, p = 0.68.
Participants who smoke tended to be taller (66.4±4.2 inches versus 65.7±3.9 inches, p<0.001),
leaner (172.3±37.1 lbs versus 176.9±36.2 lbs, p = 0.087) and had a significantly lower BMI
(28.3±5.6 versus 29.7±5.6, p<0.001). Smokers were more likely to be on anti-platelet medication (75% versus 65%, p = 0.012), and were on fewer hypertensive drugs (1.8±1.5 versus 2.1
±1.5, p = 0.015). In generalized linear models controlling for age, sex, ethnicity and BMI
(Table 2), it was found that smokers were more likely to have peripheral vascular disease
(p<0.001) and bilateral renal artery stenosis (p<0.05). The rate of diabetes amongst smokers
was significantly lower than in non-smokers (p<0.001) which may be attributable to their
younger age and leaner weight.

Smoking as a risk factor for cardio-renal events in patients with renal
artery stenosis
In order to determine whether smoking is associated with the composite endpoint in these
patients, event-free survival was plotted against age (Fig 3). Subjects were followed over a

Fig 1. CONSORT flow diagram of CORAL study.
https://doi.org/10.1371/journal.pone.0173562.g001
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Fig 2. Age in years for smokers and non-smokers at study enrollment. The Red curve represents the distribution of
age for smokers (N = 277) and the blue curve represents age at study enrollment for non-smokers (N = 644). Numbers at
the peak of the distribution curves are the mean years of age at study enrollment ± SD for the patient populations as
defined above. The insert boxplot shows age with interquartile ranges and 95% confidence intervals differentiated by
smoking status. The asterisk (*) indicates that the means are significantly different (p<0.001) as determined by two-sample
t-test.
https://doi.org/10.1371/journal.pone.0173562.g002

median follow-up of 43 months (IQR, 31 to 55). Smokers experienced these clinical events at a
significantly younger age than non-smokers. Using age-at-event to determine Cox-proportional hazard ratios, participants who smoke were 2.32 (1.79, 2.98; p<0.001) times more likely
to have a primary composite endpoint event at a younger age (67.1±9.0 vs 76.1±7.9, p<0.001)
(Table 3 and Fig 3). Additionally, smokers were more likely to experience myocardial infarction (1.82 [1.06, 3.13]; p = 0.03) (68±9.1 vs 77±7.8, p<0.001), stroke (2.59 [1.27, 5.27];
p = 0.01) (68.9±9.1 vs 77.1±7.8, p<0.001), hospitalization for congestive heart failure (2.03
[1.17, 3.52]; p = 0.01) (68±9.0 vs 77±7.8, p<0.001), progressive renal insufficiency (2.38 [1.68,
3.38]; p<0.001) (67.5±9.0 vs 76.4±7.9, p<0.001), and death due to cardiovascular or renal disease (1.77 [1.02, 3.05]; p = 0.04) (68.1±9.1 vs 77.1±7.8, p<0.001). The only secondary clinical
end-point observed not to be significantly affected by smoking was permanent renal
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Table 1. Baseline clinical characteristics comparisons by smoking status within the last year.
Baseline Characteristics*

Non-smoking (n = 654)

Smoking (n = 277)

P-value

Age (yr)

72.4±7.8

63.3±9.1

<0.001

Male sex

317(49)

133(48)

0.77

White race

584(91)

255(92)

0.53

39(6)

15(5)

0.76

United States as country origin

534(83)

233(84)

0.70

Height (in)

65.7±3.9

66.4±4.2

<0.01

Weight (lb)

176.9±36.2

172.3±37.1

0.087

29.7±5.6

28.3±-5.

<0.001

Systolic BP (mmHg)

150.8±22.7

148.4±24.2

0.15

Diastolic BP (mmHg)

77.9±12.9

80.1±13.6

0.021

158(25)

83(30)

0.10

Creatinine (mg/dl)

1.3±0.5

1.2±0.5

0.10

Cystatin C (mg/L)

1.3±0.5

1.3±0.5

0.95

MDRD-eGFR (ml/min per 1.73 m2)

59.6±22.4

65.7±27.2

0.002
<0.001

Demographic/physical examination

Hispanic/Latino

BMI (kg/m2)

Systolic BP at goal
Laboratory values (assessed by core lab)

CKD-EPI creatinine formula

56.1±20.8

63.3±24.5

CKD-EPI cystatin C formula

59.9±24.1

62.1±24.9

0.23

CKD-EPI Creatinine- cystatin C formula

58.1±21.7

62.8±25.8

<0.01
0.33

Potassium (mmol/L)
Urine albumin creatinine ratio (μg/mg)
Dipstick proteinuria  100 mg/dl

4.2±0.6

4.2±0.5

217.1±700.7

196.3±717.0

0.7

32(5)

12(4)

0.74

Angiographic findings
% stenosis, assessed by core laboratory

68.5±11.7

68.8±11.3

0.68

% stenosis, assessed visually at site

75.7±10.9

76.7±10.5

0.24

464(72)

220(80)

0.017
<0.001

Risk factors/indications
Creatinine  1.6 (mg/dl)
Peripheral vascular disease

280(44)

180(66)

Hyperlipidemia

579(90)

236(88)

0.24

Prior myocardial infarction

173(27)

86(31)

0.26

Prior transient ischemic accident

127(20)

54(20)

0.99

Angina

69(12)

34(14)

0.49

Cardiovascular disease

361(61)

164(65)

0.44

Diabetes mellitus

240(38)

66(24)

<0.001

History of heart failure

91(14)

31(11)

0.24

Chronic kidney disease

424(66)

148(53)

<0.001

CKD Stage
Mild

239(37)

95(35)

0.0021

Moderate

288(45)

107(39)

<0.001

Severe

38(6)

13(5)

0.028

113(22)

58(26)

0.3

Renin-angiotensin inhibitors

298(49)

118(49)

0.88

Diuretic

250(42)

91(37)

0.19

17(3)

9(3)

0.66

β-Blocker

319(54)

123(49)

0.18

α-Blocker

102(17)

35(13)

0.19

Bilateral disease**
Medication Use

Aldosterone antagonist

(Continued)
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Table 1. (Continued)
Non-smoking (n = 654)

Smoking (n = 277)

αβ-Blocker

Baseline Characteristics*

62(10)

31(12)

P-value
0.47

Calcium-channel blocker

239(43)

84(36)

0.057
0.19

Renin inhibitor

6(1)

0(0)

Vasodilator

33(5)

10(4)

0.40

Nitrate

115(19)

55(22)

0.40

Antiplatelet agent

361(65)

173(75)

0.012

Lipid-lowering agent

352(68)

138(61)

0.093

Total hypertensive medications

2.1±1.5

1.8±1.5

0.015

Total all medications

3.4±2.1

3.2±2

0.13

*Data are expressed as the mean±SD or number (percentage). Comparisons were evaluated using two sample t-test for continuous data or Fisher’s exact
test with odds ratio for categorical data.
**Bilateral disease was defined as stenosis of 60% or more of the diameter of at least one artery supplying each kidney.
Abbreviations: CI, confidence interval; yr, year; in, inch; lb, pound, BMI, body mass index (weight in kilograms divided by the square of the height in meters);
BP, blood pressure; MDRD-eGFR, Modification of Diet in Renal Disease-estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease
Epidemiology Collaboration; and CKD, Chronic kidney disease.
https://doi.org/10.1371/journal.pone.0173562.t001

replacement therapy (2.11 [0.82, 5.45]; p = 0.12) (68±9.0 vs 77±7.8, p<0.001), but the rate of
this event was very low.

Longitudinal analysis of smoking effect on renal and cardiovascular
function
After adjusting for age, sex, diabetes, and BMI, there was no difference observed in measures
of kidney function including serum creatinine and eGFR (Modified Diet in Renal Disease creatinine-based formula [MDRD-eGFR], Fig 4A and 4B) between smokers and non-smokers.
Urine Albumin-to-Creatinine Ratio (UACR) increased more in smokers than in non-smokers
over time and was significant at 3 years post-enrollment (Fig 4C, p<0.05). Cystatin C was also
significantly higher in patients who smoked at baseline and throughout the study period (Fig
4D, p<0.05). Similar results were observed in analysis using the Chronic Kidney Disease Epidemiologic Collaboration (CKD-EPI) formulae for creatinine, cystatin C, and GFR combining
creatinine and cystatin C (data not shown).
To further examine the longitudinal effect of smoking on kidney function, the slope of natural log of eGFR versus time for each individual was obtained by linear regression to account
for variable responses among subjects. These slopes were then used as the response variable
and fitted into a multivariate regression model with age, sex, ethnicity, smoking, diabetes and
BMI as covariates. The plot of predicted slope with 95% confidence intervals versus age at
enrollment grouped by smoking status is shown in Fig 5, which showed a trend of decreased
renal function in non-smokers that may be related to their older age, but it failed to reach statistical significance. In addition, hypertension measured by systolic or diastolic blood pressure,
and pulse pressure were not significantly different between smokers and non-smokers (Fig 6).

Discussion
We studied the effects of smoking on cardio-renal outcomes in patients with clinically significant renal artery stenosis and renovascular hypertension. The significant finding is that active
smokers presented with renal artery stenosis at a much younger age and experienced cardiorenal events at a younger age than non-smoking participants. Smoking was significantly
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Table 2. Multivariate linear regression and generalized linear regression comparing smokers and
non-smokers on baseline characteristics as the response adjusted for age, sex and ethnicity.
Baseline Characteristics

Smoking: Yes Coefficient (p-value)

Demographic/physical examination
Height (in)

0.74 (<0.002)

Weight (lb)

-14.0 (<0.001)

BMI

-3.00 (<0.001)

Systolic BP (mmHg)

0.43 (0.82)

Diastolic BP (mmHg)

-0.22 (0.83)

Angiographic findings
% stenosis, assessed by core laboratory

1.1 (0.30)

% stenosis, assessed visually

2.0 (<0.05)

Laboratory values (assessed by core lab)**
Creatinine (mg/dl)

0.014 (0.71)

MDRD-eGFR (ml/min per 1.73 m2)

-0.67 (0.72)

Cystatin C (mg/L)

0.10 (<0.01)

Potassium (mmol/L)

0.015 (0.21)

UACR (ug/mg)

-0.10 (0.50)

Risk factors/indications
Creatinine  1.6 (mg/dl)
Peripheral vascular disease

0.15 (0.43)
1.04 (<0.001)

Hyperlipidemia

-0.19 (0.47)

Prior myocardial infarction

0.14 (0.42)

Prior transient ischemic accident

0.19 (0.35)

Angina

0.25 (0.33)

Cardiovascular disease
Diabetes

0.07 (0.70)
-0.85 (<0.001)

History of heart failure

-0.34 (0.17)

Chronic kidney disease

-0.002 (0.99)

Bilateral disease***

0.45 (<0.05)

Linear model was used for continuous data and generalized linear model (GLM) for categorical factors.
** Laboratory values were log transformed when statistical analysis was performed.
*** Bilateral disease was defined as stenosis of 60% or more of the diameter of at least one artery supplying
each kidney.
Abbreviations: in: inch; lb: pound, BMI: body mass index (weight in kilograms divided by the square of the
height in meters); BP: blood pressure; MDRD-eGFR: Modification of Diet in Renal Disease-estimated
glomerular filtration rate; UACR: urine albumin creatinine ratio (measured as the log UACR).
https://doi.org/10.1371/journal.pone.0173562.t002

associated with cardiovascular or kidney death, myocardial infarction, stroke, hospitalization
for congestive heart failure and progressive renal insufficiency. Even though smokers were 9.1
years younger at enrollment, they did not differ from non-smokers in renal artery stenosis
severity. This is consistent with the known effect of smoking to accelerate atherosclerosis onset
and progression [24–26], and that smoking increases risk for renal artery stenosis [17].
The effect of active smoking on renal function was less clear in the current study. We found
no significant difference in renal function over time as evaluated by creatinine or creatininebased eGFR among smokers and non-smokers, however, cystatin C levels were significantly
higher in smokers at baseline and throughout follow up. The reason for this divergent finding
on renal function estimation is not clear. The creatinine- or cystatin C-based eGFR may not be
reliable indicators of renal function in populations who smoke as reported by Yamada [27].

PLOS ONE | https://doi.org/10.1371/journal.pone.0173562 March 17, 2017
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Fig 3. Kaplan-Meier curves of event-free survival for age-at-composite endpoint delineated by
smoking status. The hazard ratio, assessed by log-rank test for age-at-composite endpoint delineated by
smoking status, was 2.32 [1.79, 2.98], p<0.001.
https://doi.org/10.1371/journal.pone.0173562.g003

Other factors beyond renal function can influence serum cystatin C levels [28]. Since cystatin
C could be associated with inflammation [29], the observed increase of cystatin C in smokers
Table 3. Clinical events comparing smokers and non-smokers adjusted for sex, ethnicity and BMI using age-at-event (years) as the response.
Clinical Endpoint*

Smoking: Yes

Confidence Interval

P-Value

2.32

(1.79, 2.98)

<0.001

Cardiovascular or renal death

1.77

(1.02, 3.05)

0.04

Myocardial infarction

1.82

(1.06, 3.13)

0.03

Stroke

2.59

(1.27, 5.27)

0.01

Hospitalization for congestive heart failure

2.03

(1.17, 3.52)

0.01

Progressive renal insufficiency

2.38

(1.68, 3.38)

<0.001

Permanent renal replacement therapy

2.11

(0.82, 5.45)

0.12

Primary composite endpoint
Secondary clinical endpoints**

* Rows display the hazard ratio, 95% confidence interval and p-value calculated using multivariable Cox proportional-hazards regression including DBP,
peripheral vascular disease, and antihypertensive treatment. The multivariable, adjusted factors, and interaction term in the model were not significant
except for smoking which is reported.
**Each component of the primary endpoint is included for the occurrence of the event.
https://doi.org/10.1371/journal.pone.0173562.t003
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Fig 4. Longitudinal analysis of the effect of smoking on kidney function. Least square means measured over time-in-study are delineated by smoking
status, and the panels display the following: a): log values of the means for creatinine (mg/dL); b): log values of the means for MDRD-eGFR (mL/min per
1.73m2); c): log values of the means for Urine Albumin to Creatinine Ratio (mg/g); and d): log values of the means for Cystatin C (mg/L). An asterisk (*)
indicates the mean for smokers is significantly different than non-smokers value at same time point (p<0.05).
https://doi.org/10.1371/journal.pone.0173562.g004

could be due to the smoking induced inflammation. In addition, plasma creatinine level is
dependent of tissue mass and BMI. The age as well as BMI in the smokers in this study is significantly different from the non-smokers. Therefore, we adjusted the age and BMI in our
regression analysis in Table 2. It is also not clear whether smoking has any direct effect on
plasma creatinine levels. It would prudent to consider these effects when assessing renal functions in smoking populations.
Other studies have found a relationship between smoking and kidney diseases including
IgA glomerulonephritis or autosomal dominant polycystic kidney disease [3]. In the Multiple
Risk Factor Intervention Trial (MRFIT) smoking was associated with an increased risk for
ESRD and chronic kidney disease (CKD) [30]. This is supported by several other populationbased longitudinal studies from countries including the United States, Japan, and Australia

PLOS ONE | https://doi.org/10.1371/journal.pone.0173562 March 17, 2017

10 / 15

Cigarette smoking and renal artery stenosis

Fig 5. Fitted longitudinal slope of the natural log of MDRD-GFR over time-in-study by age at
enrollment. For each individual, the longitudinal slope of MDRD-GFR was obtained by linear regression
between the log of MDRD-GFR and time-in-study for that patient. These slopes were used as the response
variable and fitted into a multiple variable regression model with age, sex, ethnicity, smoking, diabetes and
BMI as covariates. The plot of the predicted slope of MDRD-GFR over time with 95% confidence intervals was
generated for age at enrollment grouped by smoking status (red for smokers and blue for non-smokers).
https://doi.org/10.1371/journal.pone.0173562.g005

with enrollments ranging between 11,247 to over 100,000 individuals [6, 9, 31–34]. The PREVEND trial found a correlation between urine albumin excretion, a marker of kidney damage,
and cigarette smoking [4–6, 8, 9, 35]. Yoon et al. found that smokers from the general population with a GFR  50 mL/min had less deterioration of kidney function but a higher risk of
proteinuria, while in those with reduced GFR (< 50 mL/min) smoking was associated with a
decline in GFR [36].
In the current study we only collected information on active smoking status and thus were
unable to distinguish former smokers from participants who have never smoked, and did not
have information on pack years and daily usage at baseline or through follow-up. This is a
common issue for studies of this type [36–41]. While more detailed data on daily smoking consumption and cumulative pack years may assist to further refine the outcomes of this study,
the overall findings remain important given the marked differences in outcomes between
smokers and non-smokers.
In summary, the current study demonstrated that active smoking results in clinical significant renal artery stenosis, and adverse cardio-renal events, at much younger age. It also clearly
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Fig 6. Longitudinal effect on blood pressure for smokers versus non-smokers. Graphs represent the following: a): systolic blood pressure
(mmHg); b): diastolic blood pressure (mmHg); and c): pulse pressure (mmHg). Mean ± SD for the patient data from baseline through follow-up
are given. No significant differences were observed.
https://doi.org/10.1371/journal.pone.0173562.g006

indicates that smoking increases the risk of deadly consequences in patients with renovascular
hypertension and indicate a need for cessation counseling for patients that currently smoke.
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